Medications for weight loss

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 22, Issue 2, 2015, Pages 91-97

  Mordes, John P ^a   Liu, Chao ^b   Xu, Shuhang ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Chinese herbal medicine; obesity; overweight; type 2 diabetes mellitus; weight loss medications

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE PLUS NALTREXONE; ANTIOBESITY AGENT; ESTERASE INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LORCASERIN; METFORMIN; NALTREXONE; PHENTERMINE PLUS TOPIRAMATE; HERBACEOUS AGENT;

BARIATRIC SURGERY; BODY MASS; CHINESE MEDICINE; DRUG APPROVAL; DRUG EFFICACY; HERBAL MEDICINE; HUMAN; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OFF LABEL DRUG USE; REVIEW; SIDE EFFECT; WEIGHT REDUCTION; COMORBIDITY; DRUG EFFECTS; PATHOPHYSIOLOGY; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME;

ANTI-OBESITY AGENTS; COMORBIDITY; DRUGS, CHINESE HERBAL; HUMANS; OBESITY; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84926382752     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000140     Document Type: Review

References (51)

1. Tsai AG, Wadden TA. In the clinic: obesity. Ann Intern Med 2013; 159:ITC3.
2. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355:763-778.
3. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999; 341:1097-1105.
4. Scully T. Public health: society at large. Nature 2014; 508:S50-S51.
5. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
6. Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374:1677-1686.
7. The Look Ahead Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity (Silver Spring) 2014; 22:5-13.
8. Ockene IS, Tellez TL, Rosal MC, et al. Outcomes of a Latino community-based intervention for the prevention of diabetes: The Lawrence Latino Diabetes Prevention Project. Am J Public Health 2012; 102:336-342.
9. Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 2007; 297:969-977.
10. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360:859-873.
11. Kruger J, Galuska DA, Serdula MK, Kohl HW III. Physical activity profiles of US adults trying to lose weight: NHIS 1998. Med Sci Sports Exerc 2005; 37:364-368.
12. Ma RCW, Lin X, Jia W. Causes of type 2 diabetes in China. Lancet Diabetes Endocrinol 2014; 2:980-991.
13. Pontiroli AE, Morabito A. Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg 2011; 253:484-487.
14. Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes (Lond) 2009; 33 (Suppl 1):S33-S40.
15. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357:753-761.
16. OBrien PE, MacDonald L, Anderson M, et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg 2013; 257:87-94.
17. Hoyton WJ. Thyroid gland in obesity. Br Med J 1906; 2:197-199.
18. Cohen PA, Goday A, Swann JP. The return of rainbow diet pills. Am J Public Health 2012; 102:1676-1686.
19. The Medical Letter. Diet, drugs and surgery for weight loss. Treatment Guidelines from The Medical Letter 2011; 9:17-22.
20. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142:532-546.
21. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335:1194-1199.
22. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diab Care 2004; 27:155-161.
23. The Medical Letter. Two drugs for weight loss. The Medical Letter on Drugs and Therapeutics 2012; 1398:69-71.
24. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebocontrolled trial of lorcaserin for weight management. N Engl J Med 2010; 363:245-256.
25. ONeil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) 2012; 20:1426-1436.
26. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011; 96:3067-3077.
27. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/ topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20:330-342.
28. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlledrelease, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:1341-1352.
29. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95:297-308.
30. Smith SM, Meyer M, Trinkley KE. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother 2013; 47:340-349.
31. The Medical Letter. Contrave - a combination of bupropion and naltrexone for weight loss. The Medical Letter on Drugs and Therapeutics 2014; 1455:112-114.
32. Caixas A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther 2014; 8:1419-1427.
33. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376:595-605.
34. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011; 19:110-120.
35. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013; 21:935-943.
36. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustainedrelease/ bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diab Care 2013; 36:4022-4029.
37. Barnett AH. The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide. Diabetes Obes Metab 2012; 14:304-314.
38. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36:843-854.
39. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311:74-86.
40. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, noninferiority study. Lancet 2008; 372:1240-1250.
41. The Medical Letter. Two new GLP-1 receptor agonists for diabetes. The Medical Letter on Drugs and Therapeutics 2014; 1455:109-111.
42. Umpierrez G, Tofe PS, Perez MF, et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diab Care 2014; 37:2168-2176.
43. Nauck M, Weinstock RS, Umpierrez GE, et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diab Care 2014; 37:2149-2158.
44. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, noninferiority trial. Lancet 2014; 384:1349-1357.
45. Yan S, Li J, Li S, et al. The expanding burden of cardiometabolic risk in China: the China Health and Nutrition Survey. Obes Rev 2012; 13:810-821.
46. Gordon-Larsen P, Wang H, Popkin BM. Overweight dynamics in Chinese children and adults. Obes Rev 2014; 15 (Suppl 1):37-48.
47. Ji L, Li H, Guo X, et al. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial. PLoS One 2013; 8:e57222.
48. Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Discord Drug Targets 2008; 8:99-111.
49. Zhou Q, Chang B, Chen XY, et al. Chinese herbal medicine for obesity: a randomized, double-blinded, multicenter, prospective trial. Am J Chin Med 2014; 42:1-12.
50. Sui Y, Zhao HL, Wong VC, et al.Asystematic reviewon use ofChinesemedicine and acupuncture for treatment of obesity. Obes Rev 2012; 13:409-430.
51. DeFronzo RA, Abdul-Ghani MA. Type 2 diabetes can be prevented with early pharmacological intervention. Diab Care 2011; 34 (Suppl 2):S202-S209.